Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Visualizing ToF-SIMS Hyperspectral Imaging Data Using Color-Tagged Toroidal Self-Organizing Maps.

Gardner W, Cutts SM, Muir BW, Jones RT, Pigram PJ.

Anal Chem. 2019 Nov 5;91(21):13855-13865. doi: 10.1021/acs.analchem.9b03322. Epub 2019 Oct 7.

PMID:
31549810
2.

Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.

Konda SK, Maliki R, McGrath S, Parker BS, Robinson T, Spurling A, Cheong A, Lock P, Pigram PJ, Phillips DR, Wallace L, Day AI, Collins JG, Cutts SM.

ACS Med Chem Lett. 2017 Apr 24;8(5):538-542. doi: 10.1021/acsmedchemlett.7b00090. eCollection 2017 May 11.

3.

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.

Tarasenko N, Nudelman A, Rozic G, Cutts SM, Rephaeli A.

Invest New Drugs. 2017 Aug;35(4):412-426. doi: 10.1007/s10637-017-0448-x. Epub 2017 Mar 17.

PMID:
28315153
4.

Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts.

Konda SK, Kelso C, Medan J, Sleebs BE, Phillips DR, Cutts SM, Collins JG.

Org Biomol Chem. 2016 Nov 2;14(43):10217-10221.

PMID:
27735959
5.

Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA.

Konda SK, Kelso C, Pumuye PP, Medan J, Sleebs BE, Cutts SM, Phillips DR, Collins JG.

Org Biomol Chem. 2016 May 18;14(20):4728-38. doi: 10.1039/c6ob00561f.

PMID:
27142235
7.

Mitoxantrone, More than Just Another Topoisomerase II Poison.

Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM.

Med Res Rev. 2016 Mar;36(2):248-99. doi: 10.1002/med.21364. Epub 2015 Aug 19. Review.

PMID:
26286294
8.

Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures.

Konda SK, Wang H, Cutts SM, Phillips DR, Collins JG.

Org Biomol Chem. 2015 Jun 7;13(21):5972-82. doi: 10.1039/c5ob00526d.

PMID:
25929194
9.

Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.

Shekhar TM, Green MM, Rayner DM, Miles MA, Cutts SM, Hawkins CJ.

Mutat Res. 2015 Jul;777:23-32. doi: 10.1016/j.mrfmmm.2015.04.005. Epub 2015 Apr 15.

PMID:
25916945
10.

Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.

Cutts SM, Rephaeli A, Nudelman A, Ugarenko M, Phillips DR.

Curr Top Med Chem. 2015;15(14):1409-22. Review.

PMID:
25866273
11.

Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide.

Ankers EA, Evison BJ, Phillips DR, Brownlee RTC, Cutts SM.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5710-5715. doi: 10.1016/j.bmcl.2014.10.062. Epub 2014 Oct 23.

PMID:
25453806
12.

A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.

Tarasenko N, Cutts SM, Phillips DR, Berkovitch-Luria G, Bardugo-Nissim E, Weitman M, Nudelman A, Rephaeli A.

Biochem Pharmacol. 2014 Mar 15;88(2):158-68. doi: 10.1016/j.bcp.2014.01.023. Epub 2014 Jan 24.

PMID:
24463168
13.

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.

Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Chemother Pharmacol. 2013 Mar;71(3):809-16. doi: 10.1007/s00280-012-2049-x. Epub 2012 Dec 23.

PMID:
23263186
14.

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K, Phillips DR, Cutts SM.

Biochem Pharmacol. 2012 Jun 15;83(12):1602-12. doi: 10.1016/j.bcp.2012.02.026. Epub 2012 Mar 5.

PMID:
22414726
15.

Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor.

Tarasenko N, Cutts SM, Phillips DR, Inbal A, Nudelman A, Kessler-Icekson G, Rephaeli A.

PLoS One. 2012;7(2):e31393. doi: 10.1371/journal.pone.0031393. Epub 2012 Feb 23.

16.

Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways.

Bilardi RA, Kimura KI, Phillips DR, Cutts SM.

Biochem Pharmacol. 2012 May 1;83(9):1241-50. doi: 10.1016/j.bcp.2012.01.029. Epub 2012 Feb 2.

PMID:
22326903
17.

M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.

Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM.

Biochem Pharmacol. 2011 Dec 1;82(11):1604-18. doi: 10.1016/j.bcp.2011.08.013. Epub 2011 Aug 30.

PMID:
21889927
18.

DNA binding by pixantrone.

Adnan N, Buck DP, Evison BJ, Cutts SM, Phillips DR, Collins JG.

Org Biomol Chem. 2010 Dec 7;8(23):5359-66. doi: 10.1039/c0ob00295j. Epub 2010 Sep 24.

PMID:
20865205
19.

The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.

Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A.

Invest New Drugs. 2012 Feb;30(1):130-43. doi: 10.1007/s10637-010-9542-z. Epub 2010 Sep 23.

PMID:
20862515
20.

New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM.

J Med Chem. 2010 Oct 14;53(19):6851-66. doi: 10.1021/jm901894c.

PMID:
20860366
21.

In vitro transcription assay for resolution of drug-DNA interactions at defined DNA sequences.

Evison BJ, Phillips DR, Cutts SM.

Methods Mol Biol. 2010;613:207-22. doi: 10.1007/978-1-60327-418-0_13.

PMID:
19997886
22.

Detection of adriamycin-DNA adducts by accelerator mass spectrometry.

Coldwell K, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR.

Methods Mol Biol. 2010;613:103-18. doi: 10.1007/978-1-60327-418-0_7.

PMID:
19997880
23.

Barminomycin, a model for the development of new anthracyclines.

Kimura K, Spencer DM, Bilardi R, Swift LP, Box AJ, Brownlee RT, Cutts SM, Phillips DR.

Anticancer Agents Med Chem. 2010 Jan;10(1):70-7. Review.

PMID:
19807684
24.

ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.

Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM.

Biochem Pharmacol. 2010 Feb 1;79(3):339-49. doi: 10.1016/j.bcp.2009.09.004. Epub 2009 Sep 6.

PMID:
19737541
25.

CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.

Evison BJ, Bilardi RA, Chiu FC, Pezzoni G, Phillips DR, Cutts SM.

Nucleic Acids Res. 2009 Oct;37(19):6355-70. doi: 10.1093/nar/gkp700. Epub 2009 Aug 31.

26.

Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.

Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR.

Nucleic Acids Res. 2008 Sep;36(16):e100. doi: 10.1093/nar/gkn439. Epub 2008 Jul 16.

27.

Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.

Evison BJ, Chiu F, Pezzoni G, Phillips DR, Cutts SM.

Mol Pharmacol. 2008 Jul;74(1):184-94. doi: 10.1124/mol.108.045625. Epub 2008 Apr 15.

PMID:
18413664
28.

Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy.

Ugarenko M, Chan CK, Nudelman A, Rephaeli A, Cutts SM, Phillips DR.

Oncol Res. 2009;17(7):283-99.

PMID:
19408574
29.

Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.

Levovich I, Nudelman A, Berkovitch G, Swift LP, Cutts SM, Phillips DR, Rephaeli A.

Cancer Chemother Pharmacol. 2008 Aug;62(3):471-82. Epub 2007 Nov 21.

PMID:
18030472
30.

DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.

Spencer DM, Bilardi RA, Koch TH, Post GC, Nafie JW, Kimura K, Cutts SM, Phillips DR.

Mutat Res. 2008 Feb 1;638(1-2):110-21. Epub 2007 Sep 16.

PMID:
17961607
31.

Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.

Cutts SM, Nudelman A, Pillay V, Spencer DM, Levovich I, Rephaeli A, Phillips DR.

Oncol Res. 2005;15(4):199-213.

PMID:
17822280
32.

The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.

Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR.

Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49. Epub 2007 Jun 27.

PMID:
17594094
33.

Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

Evison BJ, Mansour OC, Menta E, Phillips DR, Cutts SM.

Nucleic Acids Res. 2007;35(11):3581-9. Epub 2007 May 5.

34.

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity.

Rephaeli A, Waks-Yona S, Nudelman A, Tarasenko I, Tarasenko N, Phillips DR, Cutts SM, Kessler-Icekson G.

Br J Cancer. 2007 Jun 4;96(11):1667-74. Epub 2007 May 1.

35.

Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.

Cutts SM, Swift LP, Pillay V, Forrest RA, Nudelman A, Rephaeli A, Phillips DR.

Mol Cancer Ther. 2007 Apr;6(4):1450-9.

36.

Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.

Engel D, Nudelman A, Levovich I, Gruss-Fischer T, Entin-Meer M, Phillips DR, Cutts SM, Rephaeli A.

J Cancer Res Clin Oncol. 2006 Oct;132(10):673-83. Epub 2006 Jul 7.

PMID:
16826403
37.

Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.

Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Res. 2006 May 1;66(9):4863-71.

38.

The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.

Rephaeli A, Entin-Meer M, Angel D, Tarasenko N, Gruss-Fischer T, Bruachman I, Phillips DR, Cutts SM, Haas-Kogan D, Nudelman A.

Invest New Drugs. 2006 Sep;24(5):383-92.

PMID:
16502348
39.

Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR.

Curr Med Chem Anticancer Agents. 2005 Sep;5(5):431-47. Review.

PMID:
16178771
40.

The power and potential of doxorubicin-DNA adducts.

Cutts SM, Nudelman A, Rephaeli A, Phillips DR.

IUBMB Life. 2005 Feb;57(2):73-81. Review.

41.

In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.

Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z, Nudelman A.

Int J Cancer. 2005 Aug 20;116(2):226-35.

42.

The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.

Nudelman A, Levovich I, Cutts SM, Phillips DR, Rephaeli A.

J Med Chem. 2005 Feb 24;48(4):1042-54.

PMID:
15715472
43.

Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.

Parker BS, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Oncol Res. 2004;14(6):279-90.

PMID:
15206490
44.

A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences.

Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR.

J Biol Chem. 2004 Apr 30;279(18):18814-23. Epub 2004 Feb 12.

45.

Sequence specificity of adriamycin-DNA adducts in human tumor cells.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR.

Mol Cancer Ther. 2003 Jul;2(7):661-70.

46.

Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S.

Cancer Biol Ther. 2003 May-Jun;2(3):259-63.

PMID:
12878861
47.

Detection of labile anthracycline-DNA adducts by real-time PCR.

Spencer DM, Cutts SM, Kimura K, Gray PJ, Phillips DR.

Oncol Res. 2003;13(11):479-89.

PMID:
12812362
48.

Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.

Swift LP, Cutts SM, Rephaeli A, Nudelman A, Phillips DR.

Mol Cancer Ther. 2003 Feb;2(2):189-98.

49.

Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).

Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR.

Cancer Res. 2001 Nov 15;61(22):8194-202.

50.

Barminomycin functions as a potent pre-activated analogue of Adriamycin.

Moufarij MA, Cutts SM, Neumann GM, Kimura K, Phillips DR.

Chem Biol Interact. 2001 Nov 28;138(2):137-53.

PMID:
11672697

Supplemental Content

Loading ...
Support Center